Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

New selective dual alpha1A/1D adrenoreceptor antagonists reported by Janssen

Oct. 11, 2006

New alpha1A receptor antagonists for BPH prepared and tested at Ranbaxy

Oct. 5, 2006

Ozarelix improves clinical symptoms of BPH in phase II trial

Oct. 5, 2006

Elocalcitol shows no benefit for pelvic pain in phase IIa study

Oct. 2, 2006

Protox seeks Canadian clearance for phase I study of PRX-302 for BPH

Sep. 27, 2006

Nymox reports promising phase II with NX-1207 for BPH

Sep. 21, 2006

Milestone payment to AnorMED for Fosrenol approval in Germany

Sep. 20, 2006

New therapeutic agents for urological disorders imparted in recent patents

Sep. 15, 2006

Pfizer profiles its novel lead 5-HT/NA reuptake inhibitor

Sep. 13, 2006

Italian researchers present a novel selective muscarinic M3 receptor antagonist

Sep. 12, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...